@misc{indiciaee739c518b459,
  title = {Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.},
  author = {Masatoshi Kudo and Ghassan K Abou-Alfa and Zhenggang Ren and Jeong Heo and Riccardo Lencioni and Yasuaki Arai and Mohamed Bouattour and Maria A Gonzalez-Carmona and Yabing Guo and Ai-Bing Xu and Gustavo Vasconcelos Alves and Arunee Dechaphunkul and Gwo Fuang Ho and Yueh Ni Lim and HongTao Hu and Ruibao Liu and Shanzhi Gu and Vikas Ostwal and Witsarut Manasirisuk and Chang-Fang Chiu and Sri Harsha Tekumalla and Manish Shroff and Vimal Dave and Osama Rahma and Joseph P Erinjeri and Jia Fan and EMERALD-3 Investigators},
  year = {2026},
  doi = {10.1016/s1470-2045(26)00278-0},
  url = {https://pubmed.ncbi.nlm.nih.gov/42636832/},
  note = {Source identifier: 42636832}
}